NELFCD and myeloid sarcoma: Here, we have shown that i) proinflammatory Th17 and Th1 cytokines are elevated in MS patients pre-AHSCT compared to healthy controls; ii) significant and sustained reductions in proinflammatory Th17 and Th1 cytokines up to 24 months post-AHSCT that are specific to MS patients and not NHL patients; and iii) IL-17 was significantly elevated at 12 months post-AHSCT in the relapsed patients compared to non-relapse patients for MS.